Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
Eli Lilly’s Phase III SURPASS-2 clinical trial shows that treatment with tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, is associated with superior reductions in body weight and blood sugar compared with injectable semaglutide in adults with type 2 diabetes.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion.
Grand River Aseptic Manufacturing (GRAM) inked a deal with Janssen Pharmaceutical to support the manufacturing of the Johnson & Johnson company’s Covid-19 vaccine candidate.
The U.S. Food and Drug Administration granted approval of Endo International’s Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is the first FDA-approved injectable treatment for cellulite.
U.S. drugmaker Pfizer Inc. signed a long-term agreement with glass maker Corning Inc. to procure vials for storing drugs.
A panel of the European medicines regulator recommended approving Novo Nordisk’s new diabetes pill Rybelsus, further boosting prospects for the Danish drugmaker with the company’s first-of-a-kind, non-injectable treatment.
Indianapolis-based Eli Lilly is adding 462 new jobs in Durham County, North Carolina over five years.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
Researchers at the National Institutes of Health (NIH) and Massachusetts General Hospital (MGH) in Boston published research that found an injectable hormone called tesamorelin decreases liver fat and prevented liver fibrosis in HIV patients affected by non-alcoholic fatty liver disease.